Coagulation Dysfunction in Patients with Liver Cirrhosis and Splenomegaly and Its Countermeasures: A Retrospective Study of 1522 Patients
Disease Markers · 07.06.2023 · 2023 · 1-9
DOI: 10.1155/2023/5560560 ↗Kurz gefasst
Fachartikel in der Zeitschrift Disease Markers, erschienen am 07.06.2023. Verfasst von Yunfu Lv und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Hainan General Hospital (Hainan Medical College Affiliated People's Hospital), Haikou, 570311 Hainan Province, China. Hauptthemen laut MEDLINE: Splenomegaly, Blood Coagulation Disorders. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hainan Provincial Department of Science and Technology.
Abstract (Originalsprache)
Objective
Patients with cirrhosis and splenomegaly often have coagulation dysfunction which affects treatment and prognosis. This study explores the status, grading, and treatment strategies of coagulation dysfunction in patients with liver cirrhosis and splenomegaly.
Methods
A retrospective cohort study was conducted on the clinical data on consecutive patients with cirrhosis and splenomegaly treated at Hainan General Hospital, China, from January 2000 to December 2020. Starting research in January 2022.
Results
Among 1522 patients included into this study, 297 (19.5%) patients had normal results in all five coagulation tests (prothrombin time, prothrombin activity, activated partial thromboplastin time, thrombin time, and fibrinogen), and 1225 (80.5%) had coagulation dysfunction in at least one of these tests. There were significant differences ( P < 0.05 ) in treatment efficacy on these patients for three of these five coagulation tests, with the exception of prothrombin activity and thrombin time. When coagulation dysfunction was classified into grades I, II, and III based on scores from the three significant coagulation tests, prothrombin time, activated partial thromboplastin time, and fibrinogen, significant differences in surgical outcomes were found among the three grades of coagulation dysfunction and between grades I and III ( P < 0.05 ). The operative mortality rate in patients with grade III in treating liver cancer, portal hypersplenism, and/or splenomegaly was 6.5%. There was no significant difference between patients with grades I and II ( P > 0.05 ).
Conclusions
Approximately, 80% of patients with liver cirrhosis and splenomegaly had coagulation dysfunction. Surgery is feasible for grade I and II patients. For grade III patients, nonsurgical treatment should be given first, and surgery should only be considered when the coagulation function returns to normal or near-normal levels after treatment. This trial is registered with MR-46-22-009299.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Hainan General Hospital (Hainan Medical College Affiliated People's Hospital), Haikou, 570311 Hainan Province, China.
- Reproductive Medicine Center of Hainan Women and Children's Medical Center, Haikou, 570206 Hainan Province, China.
- Department of Surgery, Renhuai People's Hospital, Zunyi, 564500 Guizhou Province, China.
Förderung
- Hainan Provincial Department of Science and Technology
Zitieren
APA
Lv, Y., Liu, N., Li, Y., Wu, J., Zheng, J., Li, X., & Zeng, M. (2023). Coagulation Dysfunction in Patients with Liver Cirrhosis and Splenomegaly and Its Countermeasures: A Retrospective Study of 1522 Patients. Disease Markers, 2023, 1-9. https://doi.org/10.1155/2023/5560560
Vancouver
Lv Y, Liu N, Li Y, Wu J, Zheng J, Li X, et al. Coagulation Dysfunction in Patients with Liver Cirrhosis and Splenomegaly and Its Countermeasures: A Retrospective Study of 1522 Patients. Disease Markers. 2023;2023:1-9. doi:10.1155/2023/5560560
BibTeX
@article{Lv2023,
author = {Lv, Yunfu and Liu, Ning and Li, Yejuan and Wu, Jincai and Zheng, Jinfang and Li, Xinqiu and Zeng, Min},
title = {Coagulation Dysfunction in Patients with Liver Cirrhosis and Splenomegaly and Its Countermeasures: A Retrospective Study of 1522 Patients},
journal = {Disease Markers},
year = {2023},
volume = {2023},
pages = {1--9},
doi = {10.1155/2023/5560560}
}
EUVIMED